Literature DB >> 7374918

Dose-response relation of CSF sodium and renal sodium excretion, and its absence in homozygous Brattleboro rats.

D R Mouw, A J Vander, C Landis, S Kutschinski, N Mathias, D Zimmerman.   

Abstract

Constant intraventricular infusion (3.3--6.6 microliters/min) of artificial cerebrospinal fluid with sodium concentrations of 100, 150, 200, 250, 300, and 350 mM produced a linear dose-related change in renal sodium excretion in conscious, unrestrained Sprague-Dawley rats. The periventricular receptors stimulated were able to evoke substantial changes in body sodium balance; the 350 mM Na CSF produced an estimated 14% deficit in the content of Na in the extracellular fluid over a 5-hour infusion period. This is the first demonstration of such a dose-response relation over a wide range of CSF Na concentration (above and below normal) in conscious animals. Both the dose-response relation, and the magnitude of the effects, suggests an important physiologic role for this control mechanism. The natriuresis in response to 300 mM sodium infusion was identical in Long-Evans Brattleboro rats heterozygous for diabetes insipidus (DI), and in Sprague-Dawley rats, but was completely absent in homozygous animals. Although the experimental methods (conscious unrestrained rats) precluded simultaneous evaluation of efferent pathways other than antidiuretic hormone (ADH), the evidence from the DI rats suggests that ADH may be the efferent pathway for the response.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7374918     DOI: 10.1159/000123002

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  2 in total

1.  Cerebral regulation of renal sodium excretion in sheep infused intravenously with hypertonic NaCl.

Authors:  A Chodobski; M J McKinley
Journal:  J Physiol       Date:  1989-11       Impact factor: 5.182

Review 2.  Natriuretic hormones, endogenous ouabain, and related sodium transport inhibitors.

Authors:  John M Hamlyn
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-03       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.